Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform.
The goals of the collaboration are i) developing and validating diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing its cell and gene therapies; ii) developing new assays to enhance the potency of cell and gene therapies for use within its point-of-care (POCare) platform; and iii) developing companion diagnostics for potential enhanced patient targeting of cell and gene therapies.
Under the agreement, Orgenesis will receive worldwide, exclusive rights and licence to use and sell the kits produced by Savicell, which will include Orgenesis’ point of care network of hospitals, clinics and institutions for QC and monitoring of manufacturing and processing of autologous immune cells and autologous immune cells manipulated by cell and gene therapies.
Orgenesis intends to leverage this technology to measure the efficacy of various cell and gene therapies, as well as adaptations to enhance the potency of targeted therapies through the selection and propagation of the highly potent cells during the manufacturing process. The initial QC kit will be utilised for cell therapy treatments targeting lung cancer; however, the parties plan to expand the platform to include additional cancer types and other diseases.
